Advances in the Aetiophatogenesis of Sjögren's Syndrome - a Literature Review by Gomes PS et al.
JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH                                                                 Gomes et al.
Advances in the Aetiophatogenesis of Sjögren’s Syndrome: a 
Literature Review 
Pedro de Sousa Gomes1, Gintaras Juodzbalys2, Maria Helena Fernandes1, Zygimantas Guobis3
1Laboratory of Pharmacology and Cellular Biocompatibility, Faculty of Dental Medicine, University of Porto, Porto, Portugal.
2Department of Maxillofacial Surgery, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. 
3Department of Dental and Oral Pathology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Corresponding Author:
Pedro de Sousa Gomes
Laboratory of Pharmacology and Cellular Biocompatibility
Faculty of Dental Medicine, University of Porto
Rua Dr. Manuel Pereira da Silva
4200-393 Porto
Portugal
Tel. +351 220 901 100
Fax. +351 220 901 101
E-mail: pgomes@fmd.up.pt
ABSTRACT
Objectives: The purpose of present paper is to review and critically address the recent advances on the aetiopathogenesis of the 
Sjögren’s syndrome, taking into account the attained clinical features, with particular relevance given to the oral involvement.
Material and Methods: A comprehensive review of the available literature between 1970 and 2012, regarding to the 
aetiopathogenesis and clinical findings related to Sjögren’s syndrome was conducted. Eligible studies were identified by 
searching the electronic literature PubMed, Medline, Embase, and ScienceDirect databases for relevant reports (last search 
update January 2012), combining the MESH heading term “Sjögren’s syndrome”, with the words “salivary glands, xerostomia, 
xerophtalmia, aetiology”. The authors checked the references of the selected articles to identify additional eligible publications 
and contacted the authors, if necessary.
Results: This article addresses a large number of the recent advances in the aetiopathogenesis of the disease, taking into 
account the attained clinical features of both local and systemic nature. Detailed mechanisms of the hypothesized influence of 
viral infections, genetic and hormonal factors, and the relevance of the altered glandular homeostasis are critically discussed 
with particular relevance given to the local and systemic involvement of Sjögren’s syndrome.
Conclusions: The increasing number of data published recently on the aetiophatogenesis of Sjögren’s syndrome strengthens 
the hypothesis that this condition, as all autoimmune diseases, is a multifactor disorder. Genetic predisposition, hormonal and 
environmental factors are thought to be implicated.
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INTRODUCTION
Sjögren’s syndrome (SS) is a chronic systemic disease 
that primarily involves salivary and lachrymal glands, 
being considered an autoimmune exocrinopathy. 
The syndrome is clinically characterized by 
keratoconjunctivitis sicca and xerostomia, caused by 
inflammation – histologically identified as a focal 
lymphocytic infiltration of the affected glands [1]. 
The syndrome may appear alone, being designated as 
primary SS (pSS), or associated with other autoimmune 
disease (e.g. rheumatoid arthritis, systemic lupus 
erythematous, and systemic sclerosis), traditionally 
reported as secondary SS (sSS) [2]. 
Sjögren’s syndrome is one of the most prevalent 
autoimmune diseases, with an estimated 0.4 to 3.1 
million affected individuals in the USA alone, and 
with a female over male preponderance of 9 : 1 [3,4]. 
Although the sicca symptoms are the hallmarks of the 
syndrome, during the disease course, any organ or 
mucosal surface may be involved and patients might 
experience a huge number of clinical manifestations, 
including constitutional symptoms, arthralgias or 
arthritis, skin vasculitis, haematological disorders, 
interstitial disease of the lung, kidney failure, 
peripheral or central neuropathies and gastro-intestinal 
tract disorders. Thus, SS can be considered as a 
heterogeneous autoimmune entity that may manifest 
within a wide spectrum of disease, ranging from a 
limited organ-specific autoimmune exocrinopathy 
features, to a systemic condition with extensive 
autoimmune clinical, serological abnormalities and 
scattered complications [1,5-7]. These complexities 
have made difficult to identify homogenous group of 
patients with a shared aetiopathogenesis or prognosis. 
This is further complicated by the difficulty of reaching 
a diagnosis in the early stages of the disease, the lack 
of a specific diagnostic test for SS, and the fact that 
oral and ocular dryness are broadly common symptoms 
in the general population. Therefore, this paper aims 
to review and critically address the recent advances 
on the aetiopathogenesis of the Sjögren’s syndrome, 
taking into account the attained clinical features, with 
particular relevance given to the oral involvement.
MATERIAL AND METHODS
A comprehensive review of the available literature 
between 1970 and 2012, regarding to the 
aetiopathogenesis and clinical findings related to SS was 
conducted. Eligible studies were identified by searching 
the electronic literature PubMed, Medline, Embase 
and ScienceDirect databases for relevant reports (last 
search update January 2012), combining the MESH 
heading term “Sjögren’s syndrome”, with the words 
“salivary glands, xerostomia, xerophtalmia, aetiology”. 
The authors checked the references of the selected 
articles to identify additional eligible publications 
and contacted the authors, if necessary. This article 
addresses a large number of the recent advances in the 
aetiopathogenesis of the disease, taking into account 
the attained clinical features of both local and systemic 
nature. Detailed mechanisms of the hypothesized 
influence of viral infections, genetic and hormonal 
factors, and the relevance of the altered glandular 
homeostasis are critically discussed with particular 
relevance given to the local and systemic involvement 
of SS. However, it is not possible to comprehensively 
discuss every subject, because that would require a text 
too extensive for a single article. When appropriate, 
references are cited. 
Aetiopathogenesis
The aetiopathogenesis of SS is still obscure and 
involves several different but interrelated processes. 
The heterogeneity verified on SS advocates that the 
individual clinical manifestations result from stochastic 
interactions between the environment and a genetically-
mediated susceptible host. Given the convincing 
evidence of epithelium activation in the affected 
organs and tissues, as verified by the inappropriate 
major histocompatibility complex (MHC) expression, 
overexpression of co-stimulatory molecules and altered 
cytokine function, extensive research has focused on 
the identification of the detailed mechanisms related to 
SS establishment and development. Several hypotheses 
have been proposed to substantiate the complexity of 
SS clinical manifestations.
Genetic factors
A genetic predisposition for SS was first demonstrated 
when the disease susceptibility was associated with 
MHC Class II alleles, mainly HLA-DR and HLA-DQ 
[8]. Affected individuals of different ethnic origins 
carry different HLA susceptibilities, e.g. affected 
Caucasians from the north and western Europe showed 
a high prevalence of the haplotypes D8, DRw52 and 
DR3 [9], while Scandinavians report an association 
with DR2 [10] and Greeks with DR5 [11]. Distinct HLA 
class II haplotypes have also been correlated with the 
presence of specific autoantibodies. In fact, the presence 
of autoantibodies Ro/SSA and La/SSB – a hallmark of 
the disease – was correlated with HLA-DR3, HLA-
DQA and HLA-DQB alleles [12]. A meta-analysis of 
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worldwide conducted case control trials of SS aimed 
to identify common HLA Class II alleles contributing 
to the aetiology of pSS. At worldwide level, the most 
significant risk and protective alleles found were 
DRB1*03:01, DQA1*05:01, DQB1*02:01, DRB1*03 
and DQA1*03:01, DQA1*05:01, DQB1*05:01, 
respectively. Furthermore, the authors reported that 
common susceptibility variants where found to be part 
of a common genetic background shared between pSS 
and other autoimmune diseases [13]. 
In a distinct approach, polymorphisms of IFR-5 and 
STAT4 genes (involved in the activation of the type I 
interferon [IFN] pathway), in the leukocyte receptor 
FCGR3B and pro-inflammatory cytokine CCL3L1, were 
also found to confer susceptibility to SS development 
[14,15].
Hormonal factors
Sex hormones influence the establishment and 
development of humoral and cell-mediated immune 
responses. Estrogen is currently considered to 
be mainly responsible for gender immunological 
dimorphism and thus, decreased ovarian production of 
estrogens could be involved in the establishment and 
development of autoimmune-related syndromes. In SS, 
the perimenopausic female predominance, age onset, 
and/or disease course, in conjunction with available 
data from animal models, substantiate the putative role 
of estrogen deficiency in the etiophathogenesis of the 
disease [16]. Immunological mechanisms are related 
with the increased presentation of autoantigens to 
effector T cells, in estrogen deficitary conditions [17]. 
Androgen deficiency, both locally and systemically, 
has also been pointed out to be a key factor prompting 
SS. Reduced plasmatic levels (up to 40 - 50%) of 
dehydroepiandrosterone sulfate (DHEA-S), the 
precursor sex steroid hormone produced in the adrenal 
cortex, has been identified in SS-affected individuals, 
comparing to age and sex matched controls [18,19]. 
Furthermore, there is evidence of hypo-functioning of 
the hypothalamic-pituitary-adrenal axis in SS-affected 
women, as shown by a selective failure to produce 
DHEA-S after stimulation of the hypothalamic-
pituitary-adrenal axis with corticotropin-releasing 
hormone (CRH) [19,20]. 
Viral infections
A compelling body of evidence has been gathered 
to justify the central role of the activation of type I 
interferons (IFNs) in the establishment of SS and 
several other autoimmune conditions [21]. Type I IFNs 
are produced by many cell types including lymphocytes, 
macrophages, fibroblasts, endothelial cells and dendritic 
cells, among others, in response to viral infections. SS is 
characterized by individual clinical manifestations with 
distinct organ involvement, although the activation of 
type I IFNs is a shared and central event in SS aetiology. 
Increased type I IFNs plasmatic levels were found in 
patients with pSS. Furthermore type I IFNs mRNA 
levels were found to be increased in peripheral blood 
cells and lymphocytes, while epithelial cells positive 
for type I IFNs where detected in labial salivary 
glands of pSS-affected individuals [22]. Under these 
circumstances, the fundamental question that arises 
is the reason for the augmented production of classic 
anti-viral effector molecules, within the range of this 
autoimmune condition. Tentative candidates have been 
proposed as potential initiating factors, and virus from 
the genus Parvovirus, Cytomegalovirus, Deltaretrovirus 
and Lymphocryptovirus have been proposed [23-25]. 
Nonetheless the attained observations, more recent and 
converged evidences only allowed the establishment 
of broadly weak association between viral infections 
and the initiation of the histopathological lesion in SS 
[26,27]. Despite the unclear association, a high incidence 
of Epstein Barr virus and hepatitis C virus (HCV) 
infections have been reported, particularly in some 
restricted SS-affected populations [28]. Accordingly, 
the prevalence of antibodies to HCV, in patients with 
pSS, has been reported to range from 15 to 20%, as 
assessed by enzyme linked immunosorbent assay, and 
the detection of HCV viraemia in pSS-affected patients, 
using polymerase chain reaction, has been reported 
to range from 0 to 20% - values significantly higher 
than those attained of HCV infection in the general 
population (around 1%) [29,30].
Apart from the identification of the initiating trigger, 
the activation of the type I IFNs pathway might 
be a linkage between the innate mechanisms of 
the immunological response and the generation of 
the adaptive response, embracing only a slight glance of 
the immunoregulation process of this condition. 
Altered glandular homeostasis
Salivary glands of SS-affected individuals are 
characterized by abnormalities of glandular epithelial 
cells that occur before infiltration by auto reactive 
lymphocytes. Such idiosyncrasies include disturbed 
cell proliferation/apoptosis regulation and increased 
breakdown of secreted proteins [31]. 
Apoptosis, either in a direct or indirect way, is involved 
in the development of secretory dysfunction affecting 
the exocrine lachrymal and salivary glands [31].Two 
factors associated with acinar tissue apoptosis include 
the proteolysis of α-fodrin and the Fas/Fas-ligand 
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interaction [32]. Proteolysis of α-fodrin is pathogenic 
to cells, due to the physiological involvement of 
the intact protein in the maintenance of the normal 
membrane structure and in the support of cell surface 
protein function [33]. α-fodrin is a major target for 
caspases activity during apoptosis and its proteolysis 
leads to membrane malfunction and cellular shrinkage. 
Moreover, it has been sustained that the activation of 
the apoptotic pathway via α-fodrin fragmentation could 
determine the exposure of cryptic epitopes, which thus 
would result in the production of specific autoantibodies 
against Ro (SSA) and La (SSB) [32]. On the other hand, 
the interaction Fas/Fas-L could also contribute to the 
activation of apoptotic pathways in SS, by inducing 
the downstream activation of proteinases and caspases, 
which lead to the fragmentation of DNA. It has been 
shown that SS-affected individuals are able to express 
the Fas antigen in their ductal epithelial cells, providing 
that this cellular population is a good target for effector 
T cells-mediated induction of apoptosis [31]. Effector 
T cells are able to induce apoptosis through the 
release of proteases such as perforin and granzyme B 
[34]. Furthermore, apart from the above described 
mechanisms, the increased rate of apoptosis in acinar 
tissue cells may also result from the inequity between 
the down-regulated apoptosis inhibitor Bcl-2 and the 
up-regulated apoptosis inducer Bax [35].
Acinar and ductal cells from salivary and lachrymal 
glands of SS-affected individuals possess a molecular 
repertoire that confers an enhanced capacity to 
disorganize the extracellular matrix, in a process 
mediated by matrix metalloproteinases (MMPs). MMPs 
are a family of endopeptidases that play a fundamental 
role in tissue remodelling, both in physiological and 
pathological conditions. Their activity is regulated 
by growth factors, cytokines and hormones, as well 
as by direct interaction with constituents of the 
extracellular matrix [36]. MMPs’ biological activities 
is counterbalanced by endogenous tissue inhibitors of 
metalloproteinases (TIMPs). TIMPs are constitutively 
expressed in many tissues including exocrine glands 
and fluids [36]. In SS, the expression of MMPs, in 
particular MMP-2, MMP-3 and MMP-9, was found to be 
significantly elevated in labial salivary glands and saliva 
[37]. Moreover, the expression of TIMPs in individuals 
affected by SS are altered, specifically the MMPs/
TIMPs ratio, which would contribute to an increased 
availability of active MMPs [38,39]. Increased MMPs 
activity lead to alterations in basal and apical acinar 
and ductal cells, impairing the communication between 
these cells and their microenvironment, deregulating 
the normal vesicle traffic, thus contributing to the 
impairment of saliva secretion [40]. 
Local clinical features
Oral manifestations
Involvement of major and minor salivary glands leads to 
a decreased salivary secretion, which has a major impact 
in oral health of SS-affected individuals, affecting the 
lubricating, buffering and antimicrobial properties of 
saliva. Furthermore, patients may complain not of 
oral dryness, but of also of unpleasant taste, difficult 
eating dry food or difficulties in controlling the 
stability of removal prosthetic appliances. As a result 
of the xerostomic condition, an increased incidence of 
dental caries, mucosal friability and fungal infections 
(primarily candidiasis) is verified. Interestingly, the 
development of bacteria-related infections (such as 
those related to periodontal disease) is not enhanced 
by SS [41]. Broadly, no significant differences have 
been found, either in clinical or microflora parameters, 
of pSS- or sSS-affected patients in comparison to 
systemically healthy age- and gender-matched controls 
[42]. However, a clinical study showed that patients 
with SS and severe salivary hypofunction report an 
increased number of Streptococus mutans, Lactobacillus 
and Candida organisms in the supragingival plaque, 
while on the smooth mucosa and tongue, an increased 
frequency of Staphylococcus aureus, enterococci and 
Candida spp. were verified [43]. 
The enlargement of parotid and/or other major salivary 
glands, usually asymptomatic and self-limited, is 
also commonly verified. Episodes of acute bacterial 
sialadenitis may be frequent, with associated pain, 
trismus and tender swelling of the salivary gland. 
Accordingly, persistent enlargement should be carefully 
assessed in order to exclude bacterial super-infection 
or lymphoma development. Other oral symptoms may 
include soreness, dysphagia, alterations in the surface 
of the tongue (i.e., may become red and lobulated, with 
partial or complete depapillation, and fissures may 
appear), and in taste buds [44]. 
Ocular manifestations
Dry eye is the main ocular manifestation of SS, 
resulting from the affection of corneal and conjunctival 
epithelium, secondary to decrease of lachrymal secretion 
and altered lachrymal composition – a condition 
known as keratoconjunctivitis sicca. Interestingly, the 
lachrymal flow rate does not correlate with the severity 
of ocular manifestations [45]. 
Reported symptoms often include sensation of 
foreign-body, itching, soreness, grittiness, irritation, 
photosensitivity and thick rope-like secretions (due 
to impaired lachrymal film and abnormal mucus 
proportion), at the inner canthus [46]. Furthermore, 
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ocular complications may include corneal ulceration and 
scarring as well as occasionally perforation, bacterial 
keratitis, and eyelid infections. Ocular symptoms may 
be aggravated by reduced levels of environmental 
humidity. Enlargement of the lachrymal glands has 
been rarely reported [46].
Systemic clinical features
Musculoskeletal involvement
Joint disease associated with SS is commonly a 
polyarticular arthropathy which intermittently affects 
small joints. Evidence of joint deformity and erosion 
may be encountered in pSS-affected individuals, as 
well as nonerosive arthritis. Arthralgias, myalgias and 
fibromyalgia-like features are also commonly found 
[47].
Dermatological involvement
Dry skin is a major manifestation of SS, affecting more 
than half of SS-affected patients. Other forms of skin 
involvement, as skin rashes and altered skin sensitivity 
have also been reported, although less frequently [48]. 
Skin biopsies of patients affect by SS reveal lymphocytic 
infiltrates and it has been proposed the inclusion of skin 
biopsy as a routine analytical tool for the diagnosis 
of SS, especially in those patients with inconclusive 
histopathological analysis of minor salivary glands [49]. 
Raynaud’s phenomenon is a highly prevalent in 
patients affected by pSS and usually precedes sicca 
manifestations. Diagnosis of Raynaud’s phenomenon 
with SS has been described as intermittent attacks of 
digital pallor and/or cyanosis in the absence of any other 
related condition. The main identified triggers were 
cold and stress [50]. Also it has been correlated with an 
increased prevalence of extra-glandular manifestations 
and positive immunological markers [51].
In SS, vasculitis can vary from a cutaneous localized 
form to as systemic necrotizing vasculitis. In cutaneous 
forms, small vessel vasculitis predominates over 
medium vessel vasculitis. Further, it may either be 
lymphocytic or neutrophilic or even manifest in a hybrid 
pattern. Cutaneous vasculitis may be associated with 
mononeuritis multiplex or neuroaxial involvement, thus 
such patients often have anti-Ro antibodies, a positive 
rheumatoid factor, and mixed cryoglobulinemia included 
in the context of Waldenstrom’s macroglobulinemia 
[52]. Necrotizing vasculitis of medium-sized vessels, 
resembling polyarteritis nodosa, can occur but is a rare 
occurrence in SS patients [53].
Gastrointestinal involvement
Patients with SS are commonly affected by a varying 
degree of nonspecific esophageal motility disorders, 
and frequently gastroesophageal reflux. This converges 
to establish an increased risk of acidic reflux in the 
SS-affected patient, especially because the buffering 
capacity of the esophagus is further reduced by the 
hyposalivation [54]. Additionally, dyspepsia, moderately 
recurrent, may be associated with gastritis, reduced acid 
production, and antiparietal cell autoantibodies, but 
rarely pernicious anaemia [55]. Pancreatic involvement, 
although rare, includes pancreatitis and pancreatic 
insufficiency [55]. 
Oesophageal dysmotility can also contribute to the 
development of laryngopharyngeal reflux – caused by 
the reflux of gastric contents into the upper aerodigestive 
tract, inducing local laryngeal and neighbouring 
modifications. Acid and enzymatic activity in the peri-
oral tissues has been related to the development of 
dysphonia, chronic cough and reactive airway disease, 
throat pain and excessive throat mucus, dental caries 
and even neoplastic pathology of the larynx [56]. 
Furthermore, laryngopharyngeal reflux generally 
occurs in the absence of heartburn and oesophagitis, and 
regurgitation-related complications are mild, making 
the diagnosis challenging [56].
Renal involvement
Kidney involvement is a frequent extraglandular 
manifestation of primary Sjögren’s’s syndrome. The 
renal involvement is rarely overt, and more often follows 
a subclinical course. In some cases, it may precede the 
onset of subjective sicca syndrome [57]. Renal disease 
may manifest as tubular disease – resulting from the 
interstitial lymphocytic infiltration, with interstitial 
fibrosis and tubular atrophy – or as glomerular disease – 
resulting from immune complex deposition and 
cryoglobulinemia [58]. Tubulointerstitial nephritis 
is the most common presentation of the renal 
involvement, generally characterized by a distal 
tubular acidosis, nonetheless nephrocalcinosis, 
nephrogenic diabetes insipidus or, albeit rarely, 
proximal renal tubular acidosis or Fanconi syndrome 
have been identified [59]. Untreated disease may lead 
to an increased tendency to stone formation, and some 
patients may develop renal failure [60]. In contrast to 
interstitial disease, the presence of glomerulonephritis 
is considered a severe extraepithelial manifestation, 
albeit a far rare one. It usually appears as a late 
development of course of pSS and is correlated with 
an increased morbidity and mortality rates. The most 
commonly identified glomerulonephritis forms in pSS 
are membranoproliferative, mesangioproliferative, 
and less frequently, membranous [61]. They are 
often associated with mixed cryoglobulinemia and 
hypocomplementemia [58].
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Hepatic involvement
Liver involvement in pSS is generally rare, subclinical, 
and does not lead to cirrhosis. Elevated liver 
enzymes and antimitochondrial antibodies are the 
most sensitive indicators of underlying liver disease 
[62]. The overlap between primary biliary cirrhosis 
and pSS has, for long, been established [63]. In 
fact, both conditions share pathogenic mechanisms 
(i.e., inflammation starts around the ducts and both 
epithelial populations inappropriately express class II 
HLA molecules) despite the fact that a distinct 
autoantibody prolife is verified – patients with pSS 
usually present anti-Ro and anti-La antibodies, while 
in primary biliary cirrhosis the predominant specific 
autoantibodies are antimitochondrial antibodies 
[62]. Furthermore, the plasmatic detection of 
antimitochondrial antibodies in individuals affected 
by pSS, in the presence or absence of elevated liver 
enzymes, is highly indicative of early liver disease [55].
Pulmonary involvement
In SS-affected individuals, subclinical pulmonary 
inflammation exists in more than 30 - 50% of cases, 
and clinically significant pulmonary involvement 
can affect approximately 10% of patients and 
may be the first manifestation of the disease [64]. 
The predominant pattern of lung involvement is 
that of bronchial/bronchiolar disease, compared to 
interstitial lung disease. Other potential complications 
include lymphocytic alveolitis, lymphocytic interstitial 
pneumonitis and fibrosis, and pseudolymphoma. 
The main identified clinically symptom is cough – 
generally a symptom of xerotrachea – while the most 
commonly identified findings in radiological exams 
are ground-glass attenuation, bronchiectasis, reticular 
pattern and honeycombing, involving predominantly 
the lower lobes [65].
Neuropsychiatric involvement
Neurologic disease is one of the most common 
manifestations of SS, affecting cranial and peripheral 
nerves, and more rarely the central nervous system 
(CNS). The eclectic permutation of peripheral nervous 
system (PNS) syndromes which occur in SS patients 
are among the most common and severe extraglandular 
complications [66]. Pure or predominantly sensory 
polyneuropathies are common neurologic manifestation 
(e.g. sensory ataxic or small fibre sensory painful 
neuropathy), while mononeuropathy multiplex, 
polyradiculopathy, symptomatic dysautonomia, cranial 
neuropathy and myopathy, are rarer complications. 
Furthermore, SS patients can be affected by neuropathic 
pain, with small-fibre neuropathy causing lancinating 
or burning pain which can disproportionately affect the 
proximal torso, the extremities and the face [67].
CNS affection, which may occur with a bimodal 
temporal pattern, both at the onset of the disease and 
with a later development – is believed to be a rare but 
not negligible complication of SS. A variety of clinical 
manifestations has been recognized including diffuse, 
focal/multifocal, multiple sclerosis (MS)-like disease, 
isolated optic neuritis, transverse myelitis or psychiatric 
manifestations [68]. Interestingly, recent magnetic 
resonance imaging analysis showed that, comparing to 
controls, patients with pSS had decreased gray matter 
volume in the cortex, deep gray matter, and cerebellum. 
Associated loss of white matter volume was observed 
in areas corresponding to gray matter atrophy and in the 
corpus callosum [69].
Additionally, a relatively high rate of affective and 
cognitive symptoms, as well as abnormal fatigue 
has been reported in SS patients. They also exhibit 
a distinct pattern of personality traits and high levels of 
physiological distress [70]. 
Obstetrical and gynaecological involvement
Dyspareunia secondary to impaired lubrication is 
verified in many premenopausal women with pSS 
[71]. Other gynaecological problems include vaginal 
dryness, endometriosis, episodes of amenorrhoea 
and menorrhagia/metrorrhagia [71,72]. In one study, 
positive information about surgery for endometriosis 
has been correlated with the presence of the antibodies 
anti-SSA and anti-SSB [73].
In pSS, pregnancy does not appear to influence disease 
course. Nonetheless there is a risk of neonatal lupus and 
congenital atrioventricular bloc associated with high 
morbidity and mortality, possibly related to maternal 
anti-SSA antibodies [74].
Haematologic/oncologic involvement
Anaemia of chronic disease and hypergammaglobu-
linemia are the most prevalent hematologic 
manifestations encountered at diagnosis and during 
the course of pSS [75]. Moreover, leucopenia, T-CD4+ 
lymphocytopenia, agranulocytosis, thrombocytopenia, 
monoclonal gammopathies are also frequent 
findings, and broadly correlated with the presence of 
extraglandular symptoms, such as palpable purpura, 
lymphadenopathy, and splenomegaly [75,76].
Patients with pSS show an increased risk of lymphoma 
development and, in fact, a clinically identified condition 
occurs in about 5 - 10% of SS-affected individuals. 
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Lymphoprolipherative disorders, predominantly non-
Hodgkin’s lymphoma of B-cell origin are the most 
frequent, being marginal zone B-cell lymphomas and 
diffuse large B-cell lymphomas the most predominant 
histological types [75].
CONCLUSIONS
The increasing number of data published recently 
on the aetiophatogenesis of Sjögren’s syndrome 
strengthens the hypothesis that this condition, as all 
autoimmune diseases, is a multifactorial disorder. 
Genetic predisposition, hormonal and environmental 
factors are thought to be implicated. The absence of 
 
 
a local balance of pro-apoptotic and defensive repair 
signals seems to be the key aetiopathogenic mechanism 
leading to glandular damage. Consequently to glandular 
manifestations, the lymphocytic dysfunction seems to 
be more related to the extraglandular involvement of the 
disease. Additionally, the role of exogenous agents as 
triggering factors seems to be of relevance and needs to 
be further enlightened.
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